Coronavirus evacuees monitored at Texas Center for Infectious Disease

Facility’s primary function is to treat tuberculosis patients


The Texas Center for Infectious Disease (TCID) in San Antonio is housing at least five people who tested positive for the coronavirus after being brought to Joint Base San Antonio-Lackland, according to an article on the KSAT website.

More than 18 people have been transferred off base, either to TCID or local hospitals, after showing symptoms of the virus or while awaiting test results.

Local leaders urge Department of Defense to keep coronavirus evacuees away from local healthcare facilities

It's unclear exactly how many of those 18 people are now at TCID.

The primary purpose of TCID is to treat tuberculosis patients.

Read the article.



March 12, 2020


Topic Area: Infection Control


Recent Posts

Alleged Ransomware Administrator Extradited from South Korea

The Phobos ransomware has been used globally to target over 1,000 organizations, including healthcare.


Design Plans Unveiled for New Intermountain St. Vincent Regional Hospital

The new hospital will be a 14-floor, 737,000 square-foot facility in Billings, Montana.


Ground Broken on New Pediatric Health Campus in Dallas

The new campus will replace the existing Children’s Medical Center Dallas.


Pre-Construction Strategies for Successful Facilities Projects

Savvy decisions can help facilities meet long-term goals by creating consistency and eliminating waste.


Geisinger Finds Success with Violence Prevention Efforts

Their safety measures included training staff in de-escalation, active-shooter response drills and equipping 6,000 employees with duress notification badges.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.